In future long-term studies, plasma amino acid levels, including tyrosine and tryptophan, and clinical presentations that may suggest reduction of tryptophan or niacin, will be monitored in patients with PKU to assess the long-term effects of SLC6A19 inhibition and resulting aminoaciduria. This evidence concerns the gene SLC6A19 and phenylketonuria.